|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Mon 5/6
|
|
Download |
|
|
| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
N/A |
| Shares
Out: |
239,210,000 |
| Market
Cap: |
478.42(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $1.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amyris is a biotechnology company. Co. creates, manufactures and commercializes consumer products and ingredients. Co.'s ingredients and consumer products are powered by its fermentation-based Lab-to-Market™ technology platform. Co. has produced a renewable farnesene brand, Biofene®, a long-chain, branched hydrocarbon molecule that Co. manufactures through fermentation using engineered microbes. Co. has formulated its fermentation-based ingredients such as Squalane, Hemisqualane™, and Steviol Glycoside Rebaudioside M into its consumer brands. Co.'s consumer brands include: Biossance® clean beauty skincare, Pipette® clean baby skincare, and Purecane™ sweetener.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
17,155 |
| Total Buy Value |
$0 |
$0 |
$0 |
$69,135 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
20,999 |
4,403,696 |
| Total Sell Value |
$0 |
$0 |
$19,949 |
$15,923,478 |
| Total People Sold |
0 |
0 |
1 |
6 |
| Total Sell Transactions |
0 |
0 |
1 |
15 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kelsey Nicole |
General Counsel and Secretary |
• – – |
2017-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
21,000 |
|
- |
|
| Koninklijke Dsm N.v. |
|
• • • |
2017-08-08 |
4 |
OE |
$0.00 |
$1,123 |
I/I |
748,728 |
8,684,960 |
|
- |
|
| Koninklijke Dsm N.v. |
|
• • • |
2017-08-08 |
4 |
A |
$0.00 |
$0 |
I/I |
7,936,232 |
7,936,232 |
|
- |
|
| Reinach Fernando De Castro |
Director |
– • – |
2017-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,133 |
3,266 |
|
- |
|
| Williams R Neil |
Director |
– • – |
2017-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,133 |
2,866 |
|
- |
|
| Al Thani Sheikh Abdullah Bin Khalifa |
Director |
– • – |
2017-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,133 |
3,066 |
|
- |
|
| Eykerman Philip |
Director |
– • – |
2017-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,133 |
3,133 |
|
- |
|
| Piwnica Carole |
Director |
– • – |
2017-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,133 |
3,266 |
|
- |
|
| Klaeijsen Abraham |
Director |
– • – |
2017-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,133 |
2,466 |
|
- |
|
| Doerr L John |
Director |
– • – |
2017-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,133 |
3,266 |
|
- |
|
| Yang Patrick Y |
Director |
– • – |
2017-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,133 |
24,666 |
|
- |
|
| Melo John |
President and CEO |
• • – |
2017-06-14 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,996) |
94,448 |
|
- |
|
| Melo John |
President and CEO |
• • – |
2017-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
46,666 |
108,445 |
|
- |
|
| Doerr L John |
Director |
– • – |
2017-06-06 |
4 |
OE |
$15.00 |
$13,037,595 |
I/I |
869,173 |
869,173 |
|
- |
|
| Weaver Karen |
Principal Accounting Officer |
• – – |
2017-06-01 |
4 |
D |
$0.25 |
$42 |
D/D |
(167) |
136,754 |
|
- |
|
| Melo John |
President and CEO |
• • – |
2017-06-01 |
4 |
D |
$0.25 |
$13,469 |
D/D |
(53,238) |
926,697 |
|
- |
|
| Cherry Joel |
President of R&D |
• – – |
2017-06-01 |
4 |
D |
$0.25 |
$3,486 |
D/D |
(13,779) |
929,492 |
|
- |
|
| Eykerman Philip |
Director |
– • – |
2017-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Yang Patrick Y |
Director |
– • – |
2017-05-19 |
4 |
B |
$0.29 |
$58,380 |
D/D |
200,000 |
353,000 |
2.39 |
- |
|
| Yang Patrick Y |
Director |
– • – |
2017-05-18 |
4 |
B |
$0.29 |
$29,050 |
D/D |
100,000 |
153,000 |
2.39 |
- |
|
| Valiasek Kathleen |
Chief Financial Officer |
• – – |
2017-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
251,955 |
|
- |
|
| Cherry Joel |
President of R&D |
• – – |
2017-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
371,000 |
943,271 |
|
- |
|
| Weaver Karen |
Principal Accounting Officer |
• – – |
2017-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
69,000 |
136,921 |
|
- |
|
| Doerr L John |
Director |
– • – |
2017-05-11 |
4 |
D |
$1.00 |
$13,037,586 |
I/I |
(13,037,586) |
0 |
|
- |
|
| Cherry Joel |
President of R&D |
• – – |
2017-05-01 |
4 |
D |
$0.52 |
$13,148 |
D/D |
(25,053) |
572,271 |
|
- |
|
402 Records found
|
|
Page 9 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
